A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care

Mostrar otras versiones (1)

INTRODUCTION: Recombinant human activated protein C (APC) therapy has been shown to reduce short-term mortality in patients with severe sepsis. However, survivors of sepsis may have long-term complications affecting health-related quality of life (HRQoL) and resource utilization. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Christopher J, Heyland, Daren K, Fisher, Harold N, Fowler, Robert A, Martin, Claudio M, Day, Andrew G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246225/
https://www.ncbi.nlm.nih.gov/pubmed/18072978
http://dx.doi.org/10.1186/cc6195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246225/
https://www.ncbi.nlm.nih.gov/pubmed/18072978
http://dx.doi.org/10.1186/cc6195

Ejemplares similares